Paliperidone ER: a review of the clinical trial data

Código QR

Paliperidone ER: a review of the clinical trial data

Philip G Janicak1, Elizabeth A Winans2,31Department of Psychiatry, Rush University Medical Center, Chicago, IL, USA; 2Previously Employed by Scientific Affairs, Ortho-McNeil Janssen, LLC, Chicago, IL, USA; 3Department of Pharmacy Practice, University of Missouri Kansas City, MO, USAAbstract: Paliper...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Philip G Janicak, Elizabeth A Winans
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2007
Materias:	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/aa571f618d154d3f9c9faa4de25e763c
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Paliperidone extended-release tablets in Chinese patients with schizophrenia: meta-analysis of randomized controlled trials
por: Cai SL, et al.
Publicado: (2015)

Once-monthly paliperidone injection for the treatment of schizophrenia
por: Delia Bishara
Publicado: (2010)

Role of paliperidone extended-release in treatment of schizoaffective disorder
por: Carla M Canuso, et al.
Publicado: (2010)

The role of paliperidone extended release for the treatment of bipolar disorder
por: Marino J, et al.
Publicado: (2012)

Efficacy, safety, and impact on hospitalizations of paliperidone palmitate in recent-onset schizophrenia
por: Zhang F, et al.
Publicado: (2015)

Direct and indirect effects of paliperidone extended-release tablets on negative symptoms of schizophrenia
por: Ibrahim Turkoz, et al.
Publicado: (2008)

The social functional outcome of being naturalistically treated with paliperidone extended-release in patients with schizophrenia
por: Nakagawa R, et al.
Publicado: (2015)

Expansion of guidance for the day 8 initiation dose of paliperidone palmitate to avoid a missed dose
por: Samtani MN, et al.
Publicado: (2013)

Long-term tolerability of once-monthly injectable paliperidone palmitate in subjects with recently diagnosed schizophrenia
por: Sliwa JK, et al.
Publicado: (2012)

The cost reduction in hospitalization associated with paliperidone palmitate in the People’s Republic of China, Korea, and Malaysia
por: Chiou CF, et al.
Publicado: (2015)

An open-label, flexible-dose study of paliperidone extended-release in Chinese patients with first-onset psychosis
por: Si TM, et al.
Publicado: (2015)

Randomized, placebo-controlled, double-blind study assessing the efficacy and safety of paliperidone palmitate in Asian patients with schizophrenia
por: Takahashi N, et al.
Publicado: (2013)

Transcranial magnetic stimulation for the treatment of major depression
por: Janicak PG, et al.
Publicado: (2015)

Paliperidone palmitate and risperidone long-acting injectable in subjects with schizophrenia recently treated with oral risperidone or other oral antipsychotics
por: Alphs L, et al.
Publicado: (2013)

An open-label, prospective study to evaluate social function and overall improvement of extended-release paliperidone treatment in Thai schizophrenia patients
por: Charnsil C, et al.
Publicado: (2013)

Efficacy and safety of flexibly dosed paliperidone palmitate in Chinese patients with acute schizophrenia: an open-label, single-arm, prospective, interventional study
por: Si TM, et al.
Publicado: (2015)

Incidence and time course of extrapyramidal symptoms with oral and long-acting injectable paliperidone: a posthoc pooled analysis of seven randomized controlled studies
por: Gopal S, et al.
Publicado: (2013)

Number needed to treat and number needed to harm with paliperidone palmitate relative to long-acting haloperidol, bromperidol, and fluphenazine decanoate for treatment of patients with schizophrenia
por: Srihari Gopal, et al.
Publicado: (2011)

Aripiprazole combination for reversal of paliperidone-induced increase in prolactin level
por: Zhi P, et al.
Publicado: (2018)

Interaction between paliperidone extended release and TS-1&reg;, an oral anticancer drug containing a 5-fluorouracil derivative, in a schizophrenic patient
por: Yasui-Furukori N, et al.
Publicado: (2013)

Critical evaluation of paliperidone in the treatment of schizophrenia in Chinese patients: a systematic literature review
por: Zhang LL, et al.
Publicado: (2016)

Role of paliperidone palmitate 3-monthly in the management of schizophrenia: insights from clinical practice
por: Lopez A, et al.
Publicado: (2019)

Comparison of paroxetine and agomelatine in depressed type 2 diabetes mellitus patients: a double-blind, randomized, clinical trial
por: Kang RY, et al.
Publicado: (2015)

Predicting PTSD using the New York Risk Score with genotype data: potential clinical and research opportunities
por: Boscarino JA, et al.
Publicado: (2013)

Faster return to work after psychiatric consultation for sicklisted employees with common mental disorders compared to care as usual. A randomized clinical trial
por: Christina M van der Feltz-Cornelis, et al.
Publicado: (2010)

Distinguishing between attention-deficit hyperactivity and fetal alcohol spectrum disorders in children: clinical guidelines
por: Elizabeth Peadon, et al.
Publicado: (2010)

Aripiprazole for the management of schizophrenia in the Japanese population: a systematic review and meta-analysis of randomized controlled trials
por: Kishi T, et al.
Publicado: (2015)

A systematic review of randomized controlled trials of bupropion versus methylphenidate in the treatment of attention-deficit/hyperactivity disorder
por: Maneeton N, et al.
Publicado: (2014)

Efficacy and tolerability of aripiprazole once monthly for schizophrenia: a systematic review and meta-analysis of randomized controlled trials
por: Oya K, et al.
Publicado: (2015)

Rosa damascena oil improves SSRI-induced sexual dysfunction in male patients suffering from major depressive disorders: results from a double-blind, randomized, and placebo-controlled clinical trial
por: Farnia V, et al.
Publicado: (2015)

Efficacy and safety profile of paliperidone palmitate injections in the management of patients with schizophrenia: an evidence-based review
por: Emsley R, et al.
Publicado: (2018)

Anticonvulsant treatments of dysphoric mania: a trial of gabapentin, lamotrigine and carbamazepine in Iran
por: Naghmeh Mokhber, et al.
Publicado: (2008)

A randomized controlled trial of quetiapine for psychosis in Parkinson&rsquo;s disease
por: Paul Shotbolt, et al.
Publicado: (2009)

Risk of seizures in transcranial magnetic stimulation: a clinical review to inform consent process focused on bupropion
por: Dobek CE, et al.
Publicado: (2015)

Reasons for reoperation after epilepsy surgery: a review based on a complex clinical case with three operations
por: Jos&eacute; F T&eacute;llez-Zenteno, et al.
Publicado: (2010)

Heart rate variability measurement and clinical depression in acute coronary syndrome patients: narrative review of recent literature
por: Harris PR, et al.
Publicado: (2014)

Review of the clinical evidence for interferon &beta; 1a (Rebif&reg;) in the treatment of multiple sclerosis
por: Francesco Manfredonia, et al.
Publicado: (2008)

Clinical utility of vilazodone for the treatment of adults with major depressive disorder and theoretical implications for future clinical use
por: Singh M, et al.
Publicado: (2012)

Clinical relevance of paliperidone palmitate 3-monthly in treating schizophrenia
por: Mathews M, et al.
Publicado: (2019)

Augmentation of light therapy in difficult-to-treat depressed patients: an open-label trial in both unipolar and bipolar patients
por: Camardese G, et al.
Publicado: (2015)